UnknownPhase 2

A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:

Pakistan30 participantsStarted 2018-07-12

Plain-language summary

Severe and very severe aplastic anemia are life threatening disorders for which allogeneic stem cell transplant is only curative treatment. However, matched sibling donor (MSD) is available in only 25-35% cases. Pakistan has a population of around 203 million but there is no donor registry available so there is no option available for matched unrelated donor (MUD) transplants . Haploidentical transplant represents only curative option for patients lacking MSD. Protocols involving post transplant cyclophosphamide require Total body irradiation (TBI) and utilize peripheral blood stem cell(PBSC) as graft source. TBI is not available in most of transplant centres across Pakistan due to lack of availability , cost and lack of expertise. The investigators have conceived a novel TBI free conditioning regimen to be used for haplo-identical Hemtopoeitic stem cell transplant in acquired aplastic anemia patients

Who can participate

Age range2 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>2 years and \< 60 years * Karnofsky performance status \>= 70% * Aplastic Anemia that meets the following criteria: i. Peripheral Blood (must fulfill 2 of 3): ii. \<500 neutrophils iii. \<20,000 platelets iv. absolute reticulocyte count \<40,000/microL * Bone Marrow (must be ): markedly hypocellular (\<25% of normal cellularity) with absence of reticulin and abnormal infiltrate Exclusion Criteria: * Presence of donor specific antibodies * Fanconi anemia * Cytogenetic abnormalities suggestive of myelodysplastic syndrome * Prior HSCT * Human immunodeficiency virus infection * Active Hepatitis B virus infection * Active /uncontrolled bacterial, viral , fungal infection or Tuberculosis * Psychiatric illness * Poor cardiac function (ejection fraction \<40%) * Poor pulmonary function (Forced vital capacity \<50% predicted) * Poor liver function (bilirubin \>= 2mg/dL) * Poor renal function (creatinine \>= 2.0mg/dL or creatinine clearance \<40)

What they're measuring

Number of Participants with overall survival

Timeframe: from the date of transplant to 1 year post transplant

Trial details

NCT IDNCT03955601

SponsorNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2020-12-30

Contact for this trial

Xanab akram

03325346564 xanab.akram@gmail.com